Patients who received the original monovalent mRNA COVID-19 vaccine were less likely than unvaccinated patients to be hospitalized for COVID-19-associated VTE.

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Traditional vaccines typically focus on the most accessible parts of viruses, which are often the rapidly mutating ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.

Not long after the Illinois Department of Health announced the state’s overall respiratory illness cases had reached the ...